Xcout Intel
Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company that uses structure-based drug discovery and computational chemistry to develop small-molecule medicines. It focuses on therapeutic areas including oncology, autoimmune disease, and metabolic disorders, serving patients through internally developed programs and pharmaceutical partnerships.
Subscribe to see Nimbus Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nimbus Therapeutics at a glance
Nimbus Therapeutics is a biotech company. It has raised at least $252M across the 4 funding rounds on record. Its most recent funding round, Growth, raised $125M in September 2022. Xcout tracks 11 named people at Nimbus Therapeutics, including Abbas Kazimi (Chief Executive Officer). Xcout recorded 2 job postings from Nimbus Therapeutics in the last 90 days.
Nimbus Therapeutics leadership
- Abbas KazimiChief Executive Officer
- Peter J. TumminoPresident of Research & Development
- Ian SandersonChief Financial Officer
- Anita ScheuberSenior Vice President, Therapeutic Area Head, Oncology
- Fang WangSenior Vice President, Biology
- Scott EdmondsonSenior Vice President, Chemistry
5 more named people on record for Nimbus Therapeutics, with roles, board committees and tenure — see the full roster →
Nimbus Therapeutics funding rounds
At least $252M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Growth | $125M | — | |
| Growth | $60M | — | |
| Series B | $43M | 2 named | |
| Series A | $24M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Nimbus Therapeutics
Xcout recorded 2 job postings from Nimbus Therapeutics in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Nimbus Therapeutics's hiring signals →
Investors
Nimbus Therapeutics competitors
A few of Nimbus Therapeutics's closest competitors — see the full list of competitors and alternatives →
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Ditto Biosciences is a company headquartered in San Francisco, US, that focuses on drug discovery. The company is involved in identifying proteins that could lead to new drugs for patients with autoimmune diseases.
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Get Nimbus Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nimbus Therapeutics in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access